BLC
EW icon

Blue Line Capital’s Edwards Lifesciences EW Stock Holding History

Blue Line Capital’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$986K Buy
10,901
+1,516
+16% +$127K 0.82% 40
2026
Q1 		$752K Buy
9,385
+605
+7% +$49.9K 0.85% 42
2025
Q4 		$748K Buy
+8,780
New +$721K 0.88% 40

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Blue Line Capital's EW Position: Q2 2026 in Review

Blue Line Capital increased its Edwards Lifesciences (EW) stake by 16% in Q2 2026, buying an estimated $127K and bringing the position to 10,901 shares worth $986K. The position accounts for 0.82% of the portfolio, ranked #40.

Blue Line Capital first reported a position in EW in Q4 2025 and has held it in 3 quarters since. 1,330 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Blue Line Capital held 10,901 shares of Edwards Lifesciences worth $986K as of Q2 2026.
  • Blue Line Capital bought 1,516 Edwards Lifesciences shares in Q2 2026, an estimated $127K.
  • Edwards Lifesciences made up 0.82% of Blue Line Capital's portfolio in Q2 2026, its #40 holding.
  • Blue Line Capital first reported a position in Edwards Lifesciences in Q4 2025 and has held it in 3 quarters since.
  • 1,330 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Blue Line Capital's 13F filing for Q2 2026, filed 30 Jul 2026.